(-0.03%) 5 476.75 points
(-0.04%) 38 803 points
(0.01%) 19 923 points
(0.29%) $80.56
(1.11%) $2.82
(0.12%) $2 331.70
(-0.36%) $29.29
(-0.13%) $969.60
(0.02%) $0.932
(-0.12%) $10.64
(0.08%) $0.788
(-1.87%) $86.80
Live Chart Being Loaded With Signals
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics...
Stats | |
---|---|
Šios dienos apimtis | 214 314 |
Vidutinė apimtis | 376 261 |
Rinkos kapitalizacija | 942.18M |
EPS | $-0.620 ( Q1 | 2024-05-02 ) |
Kita pelno data | ( $-1.100 ) 2024-08-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-5.02 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0540 (0.24%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-29 | Baker Bros. Advisors Lp | Buy | 15 684 860 | Non-Voting Ordinary Shares |
2024-05-29 | Baker Bros. Advisors Lp | Buy | 1 429 986 | Non-Voting Ordinary Shares |
2024-04-18 | Baker Bros. Advisors Lp | Buy | 12 000 | American Depositary Shares |
2024-04-18 | Baker Bros. Advisors Lp | Buy | 12 000 | American Depositary Shares |
2024-04-18 | Baker Bros. Advisors Lp | Buy | 24 000 | Share Option (Right to Buy) |
INSIDER POWER |
---|
98.19 |
Last 94 transactions |
Buy: 18 560 846 | Sell: 230 741 |
Tūris Koreliacija
Bicycle Therapeutics PLC Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
OZEM | 1 |
MAMA | 0.951 |
HLP | 0.943 |
NBBK | 0.935 |
MSAQX | 0.934 |
FSMSX | 0.932 |
EVCGX | 0.931 |
MICFX | 0.925 |
MCHFX | 0.924 |
EQ | 0.907 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
GBLMX | -0.945 |
NWGL | -0.931 |
QREARX | -0.926 |
CYAN | -0.91 |
FINW | -0.908 |
WTER | -0.904 |
VIVE | -0.898 |
HTOOW | -0.896 |
PLTN | -0.895 |
FUFUW | -0.895 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Bicycle Therapeutics PLC Koreliacija - Valiuta/Žaliavos
Bicycle Therapeutics PLC Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $26.98M |
Bruto pelnas: | $20.40M (75.64 %) |
EPS: | $-5.08 |
FY | 2023 |
Pajamos: | $26.98M |
Bruto pelnas: | $20.40M (75.64 %) |
EPS: | $-5.08 |
FY | 2022 |
Pajamos: | $14.46M |
Bruto pelnas: | $10.78M (74.51 %) |
EPS: | $-3.80 |
FY | 2021 |
Pajamos: | $11.70M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-2.67 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Bicycle Therapeutics PLC
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.